These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15961357)

  • 1. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
    Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
    Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
    Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
    Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
    Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of a semiquantitative spinal deformity index.
    Crans GG; Genant HK; Krege JH
    Bone; 2005 Aug; 37(2):175-9. PubMed ID: 15922683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
    Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
    Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
    Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
    Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.
    Prevrhal S; Krege JH; Chen P; Genant H; Black DM
    Curr Med Res Opin; 2009 Apr; 25(4):921-8. PubMed ID: 19250060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.